Valeant Pharmaceuticals International

Valeant is working to build a significant dermatology portfolio through both acquisitions and internal growth. Valeant's dermatology sales force currently focuses on promoting Kinerase® and Efudex®/Efudix®, but also sells a number of other successful brands including Oxsoralen-Ultra®, Dermatix™, Glyquin®, Solaquin® and Eldoquin® in markets throughout the world.

For information about Valeant's dermatology products, please visit the individual product Web sites.

TARIBAVIRIN and RETIGABINE are products in clinical development. None of them have been found to be safe or effective for the treatment of any disease or illness. They may not be sold or promoted in the United States unless and until they are approved by the FDA. Similar restrictions apply in other countries.